Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea

Health Canada carried out a safety review to look into the risk of sleep apnoea with the use of atypical antipsychotics. Sleep apnoea is a disorder that causes breaks in breathing or shallow breaths during sleep. This review was triggered by the submission of new safety information from the manufacturer of quetiapine (Seroquel) that included cases of sleep apnoea in patients using quetiapine.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Résumé de l'examen de l'innocuité – Antipsychotiques atypiques – Évaluation du risque potentiel d'apnée du sommeil
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2020-12-04 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Résumé de l'examen de l'innocuité", "antipsychotiques atypiques", "évaluation", "risque potentiel", "apnée du sommeil", "apnée du sommeil", "antipsychotiques atypiques", "troubles", "pauses respiratoires", "respirations superficielles", "informations de sécurité", "fabricant", "quétiapine (Seroquel)"], "en": ["Summary Safety Review", "Atypical antipsychotics", "assessing", "potential risk", "Sleep Apnoea", "sleep apnoea", "atypical antipsychotics", "disorder", "breaks in breathing", "shallow breaths", "safety information", "manufacturer", "quetiapine (Seroquel)"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source